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Abstract : We had found previously that calcitonin treatment （elcatonin once a 
week for 10 weeks） results in signicant decreases in blood pressure.  The aim of 
the present study was to determine whether these effects were due to a cumulative 
effect of elcatonin or could be elicited by treatment with a single dose.  To this 
end, we recruited 62 patients （eight men, 54 women ; mean age 83 years ; range 
67–101 years） with a chief complaint of lower back pain to the present study and 
examined changes in blood pressure following administration of the first dose of 
elcatonin.  All subjects in the study had been hospitalized either at our institution 
or an afliated hospital.  After acute phase symptoms had settled, subjects received 
1 U （1 mL）, i.m., elcatonin S20.  Blood pressure was measured the day before the 
rst scheduled treatment and on the day of treatment.  Both systolic and diastolic 
blood pressure decreased from 2 h after administration, and dropped significantly 
4 and 6 h after administration.  Therefore, elcatonin decreased blood pressure 
without first having to be accumulated in the body.  There are several possible 
explanations for the results, including effects mediated by changes in concentrations 
of calcitonin gene-related peptide and calcium ions, as well as involvement of the 
parasympathetic nervous system.  In conclusion, calcitonin inhibits bone resorption 
and pain, lowers blood pressure, and is easy to use in elderly patients who exhibit 
age-related increases in blood pressure.
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Introduction
　Elcatonin is a calcitonin derivative that has an inhibitory effect on osteoporosis-related pain 
that is mediated via the serotonergic system 1, 2）.  In addition, it has been reported that elcatonin 
increases skin temperature 3） and blood flow 4）, improves brachial-ankle pulse wave velocity, 
and decreases blood pressure 5, 6）.  Tissue blood flow improved significantly in individuals with 
decreased blood flow after the administration of elcatonin, and elcatonin has a significant 
hypotensive effect in patients with high compared with low blood pressure 6） （Fig. 1）.  Generally, 
calcitonin is the only hormone that has been shown to lower serum calcium levels in vivo and 
to decrease high blood pressure and improve blood flow.  In a previous study 6）, we found that 
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elcatonin treatment （once a week for 10 weeks） resulted in significant decreases in blood pressure 
compared with values in untreated patients.  This hypotensive effect was thought to be due to the 
vasodilatory effect of calcitonin, although it was unclear whether it was due to a cumulative effect 
of 10 treatments or the result of a single dose of elcatonin.  Therefore, the aim of the present 
study was to determine changes in blood pressure following the first administration of elcatonin.
Methods
Subjects
　Sixty-two subjects （eight men, 54 women ; mean age 83 years ; range 67–101 years） with a 
chief complaint of lower back pain （thoracic compression fracture, lumbar spine compression 
fracture, lumbar spondylosis, spinal canal stenosis, spondylolisthesis, and muscular lower back 
pain） who had been admitted to our hospital or an affiliated hospital between 2009 and 2011 
were recruited to the present study.  Prior to their inclusion in the study, subjects were given an 
explanation of the study, including protection of personal information and ethical considerations, 
and were asked to provide oral or written consent.
Methods
　After acute phase symptoms had settled and the subject was ambulatory and no longer 
required the use of a wheelchair, 1 U, i.m., elcatonin S20 （1 mL） was administered.  Blood 
pressure was measured the day before the first scheduled treatment with elcatonin and on the 
day of treatment.  Elcatonin was administered at 0900 hours and blood pressure was measured 
Fig. 1.  Pharmacological effect of elcatonin （ECT）. baPWV, brachial-ankle pulse wave velocity.
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at the same time on both days （i.e. 1000, 1100, 1300, 1500, and 1700 hours） to minimize the 
effects of diet and rehabilitation on blood pressure fluctuations.  Patients taking non-steroidal 
anti-inflammatory or antihypertensive drugs were maintained on these drug regimens at the same 
dosage and were given the drugs at the same time on both days.  Blood pressure was measured 
using a manual sphygmomanometer after subjects had rested on a bed for 10 min.
Statistical analysis
　Results are presented as the mean ± SD.  For statistical analysis, blood pressure values taken 
at the same time on the day before and on the day of elcatonin treatment were compared using 
Student’s t-test.  Two-sided P＜0.05 was considered significant.  All analyses were performed 
using Stat Mate III ver. 3.14 （ATMS, Tokyo, Japan）.
Results
Systolic blood pressure
　Mean systolic blood pressure in all patients on the day before treatment at 1000, 1100, 
1300, 1500, and 1700 hours was 127.4 ± 20.3, 131.0 ± 18.9, 126.3 ± 17.0, 131.6 ± 20.2, and 138.2 ±
22.5 mmHg, respectively.  On the day of treatment, mean systolic blood pressure in all patients 
at 1000, 1100, 1300, 1500, and 1700 hours was 130.8 ± 20.6 （P＝0.19）, 128.0 ± 19.2 （P＝0.22）, 
121.5 ± 18.2 （P＜0.05）, 126.5 ± 18.8 （P＜0.05）, and 134.9 ± 22.1mmHg （P＝0.22）, respectively, 
with significant decreases in systolic blood pressure 4 and 6 h after the administration of 
elcatonin compared with values obtained at the same time the previous day （Fig. 2）.
Fig. 2.  Changes in systolic blood pressure the day before and on the same day of 
elcatonin administration. After injection of elcatonin, systolic blood pressure 
increased once, but was generally lower than on the day before, with signicant 
decreases observed 4 and 6 h after administration. Data are the mean ± SD.
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Diastolic blood pressure
　Mean diastolic blood pressure in all patients on the day before treatment at 1000, 1100, 1300, 
1500, and 1700 hours was 71.0 ± 11.5, 72.8 ± 13.6, 70.1 ± 13.1, 73.6 ± 12.4, and 76.2 ± 12.3 mmHg, 
respectively.  On the day of treatment, mean diastolic blood pressure in all patients at 1000, 
1100, 1300, 1500, and 1700 hours was 72.8 ± 14.9 （P＝0.28）, 70.8 ± 14.0 （P＝0.32）, 66.0 ±12.7 
（P＜0.01）, 68.9 ± 12.2 （P＜0.05）, and 73.3 ± 12.2 （P＝0.09）, respectively, with significant 
decreases seen 4 and 6 h after elcatonin treatment compared with values obtained at the same 
time the previous day （Fig. 3）.
Discussion
　Both systolic and diastolic blood pressure decreased ≥2 h after injection of elcatonin compared 
with values obtained the day before treatment, with a general trend for lower blood pressure 
after the administration of elcatonin compared with values obtained the previous day.  Blood 
pressure levels were particularly low 4 and 6 h after elcatonin injection ; therefore, elcatonin 
appears to decrease blood pressure without first having to accumulate in the body.
　Elcatonin absorption following intramuscular injection is rapid, with peak plasma concentrations 
of approximately 30 pg / mL observed 30 min after administration of 20 U elcatonin 7）.  However, 
pharmacokinetic analysis has revealed a half-life of 20.8 min for elcatonin and an absorption lag 
time of 5.5 min 8）.  Based on these values, serum elcatonin concentrations were quite low 4 and 
Fig. 3.  Changes in diastolic blood pressure the day before and on the same day of 
elcatonin administration. After injection of elcatonin, diastolic blood pressure 
increased once, but was generally lower than on the day before, with signicant 
decreases observed 4 and 6 h after administration. Data are the mean ± SD.
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6 h after administration when the significant decreases in blood pressure were observed.  There 
could be several factors contributing to the changes in blood pressure other than a direct action 
of calcitonin, including the actions of substances with a long half-life, such as calcitonin gene-
related peptide （CGRP）.  The common calcitonin / CGRP gene on chromosome 11 is made 
up of six exons ; calcitonin is encoded by exon 4 and CGRP is encoded by exons 5 and 6 9）. 
Calcitonin is produced by thyroid C cells through tissue-specific splicing, whereas CGRP is 
produced by neurons that are widely distributed throughout the cardiovascular system, but are 
more common in the arterial than venous system 10）.  CGRP and calcitonin reportedly share 
20％ homology 11）, and calcitonin has a vasodilatory effect via CGRP-like activity.  Another 
factor that could have contributed to the changes in blood pressure seen in the present study 
is lowering of calcium ion levels.  Because the production of calcitonin results in decreases 
in extracellular calcium levels, there is a consequent decrease in calcium influx into cells via 
calcium-sodium transporters 12）, resulting in a decrease in the opening of calcium-dependent 
calcium channels in the sarcoplasmic reticulum 13）.  This weakens the contractile force of the 
cardiovascular system and subsequently decreases blood pressure.  In addition, changes in blood 
pressure following the injection of elcatonin may involve effects of the parasympathetic nervous 
system.  Calcitonin administration induces descending pain inhibition via the serotonergic system ; 
following pain alleviation, the parasympathetic nervous system becomes dominant, resulting 
in vasodilation 1）.  This mechanism is considered to be important based on studies reporting 
significant therapeutic effects of elcatonin administered for the treatment of reflex sympathetic 
dystrophy 14）.  Furthermore, calcitonin administration restores serotonin receptor levels, decreases 
the release of glutamic acid, and eliminates hypersensitivity, thereby improving osteoporosis 
pain 1）.  However, serotonin receptor levels are restored following repeated dosing with elcatonin, 
and not after treatment with a single dose, thus it remains unclear whether the effects of the 
parasympathetic nervous system on blood pressure are predominant after the administration of a 
single dose of elcatonin.
　In Japan, the drugs used in the treatment of osteoporosis have changed considerably in recent 
years.  For example, bisphosphonates, including alendronate and risedronate, are commercially 
available and are taken once a week ; oral minodronate and intravenous alendronate are taken 
once a month.  In 2010, the selective estrogen-receptor modulators raloxifene and bazedoxifene, 
as well as drugs inhibiting bone resorption, such as vitamin D3 and eldecalcitol, were introduced 
in addition to calcium and vitamin K2 treatment 15）.  Parathyroid hormone effectively promotes 
osteogenesis, whereas calcitonin inhibits bone resorption 16） and acts to inhibit pain.  Furthermore, 
drugs that also have hypotensive effects are considered safe and easy to use in elderly patients 
with age-induced increases in blood pressure.  Therefore, tailored treatment for individual patients 
using suitable drug combinations is recommended in these cases.
　Systolic and diastolic blood pressure levels were decreased significantly between 4 and 6 h after 
administration of the calcitonin analog elcatonin, which was found to be effective, safe, and easy 
to use in elderly patients with osteoporosis.
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